Organisation paid for research Program year 2025 Source: CMS Open Payments

Wright State Physicians

Neither a doctor nor a teaching hospital

Research payments

$1,289,975

207 payments

Through program year 2025, Wright State Physicians is reported as receiving $1,289,975 in research payments, across 207 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$53,714	11
2024	Research	$82,044	14
2023	Research	$124,256	36
2022	Research	$143,000	46
2021	Research	$452,822	52
2020	Research	$288,638	39
2019	Research	$145,499	9

Breakdown

Who paid Research payments · program years 2019–2025

Amgen Inc. $780,369 52 payments
Kiniksa Pharmaceuticals, Ltd. $184,539 87 payments
Celgene Corporation $106,692 5 payments
E.R. Squibb & Sons, L.L.C. $62,047 5 payments
Arcutis Biotherapeutics, Inc. $23,968 14 payments
Horizon Therapeutics plc $22,984 2 payments
Organon LLC $22,951 7 payments
AbbVie, Inc. $20,349 5 payments
Eli Lilly and Company $19,522 17 payments
Argenx US, Inc. $18,920 4 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 2a/b, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of KPL-716 in Reducing Pruritis in Subjects with Prurigo Nodularis $200,765 88 payments
Ppso-003/20200056 (Sprout) $199,527 2 payments
Efficacy/Safety Study of Apremilast in Pedi Subjects With Moderate to Severe Plaque PSO (PPSO-003) $195,219 28 payments
PPSO-004/20200057 (SPROUT Rollover) $163,936 2 payments
A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, STUDY OF THE EFFICACY AND SAFETY Of APREMILAST (CC-10004), COMPARED TO PLACEBO, IN SUBJECTS WTIH MILD TO MODERATE PLAQUE PSORIASIS (CC-10004-PSOR-022) $104,994 2 payments
Efficacy/Safety study of Apremilast in subjects with Mild-to-moderate Plaque Psoriasis (PSOR-022) $58,780 2 payments
Ph3b Otezla in Peds mod/sev PsO (SPROUT rollover) $38,145 2 payments
P2 Moderate-Severe pDLE $34,353 2 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Moderate to Severe Psoriasis $30,329 1 payment
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects $22,951 7 payments

What the money was spent on Research payments · program years 2019–2025

Patient care $22,951 7 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.